RPCEC00000082已完成4 期
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods (hemodialysis or peritoneal dialysis).
Center of Molecular Immunology(CIM)0 个研究点目标入组 621 人开始时间: 2009年7月10日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 621
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 none（—）
- 性别
- All
入选标准
- •1.Patients with inform consent signed. 2.Patients with stable dialysis treatment at least of 3 months prior. 3.Patients who are receiving ior EPOCIM for the treatment of anemia associated with CRF. 4.Age less than 18 years. 5.To be included in the study patients of both sexes.
排除标准
- •1.Patients with known hypersensitivity to products derived from cells above or hypersensitivity to human albumin. 2.Patients pregnant or breastfeeding.
研究者
相似试验
招募中
4 期
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis.Anemia secondary to Chronic Kidney DiseaseRPCEC00000123CIMAB-Center of Molecular Immunology (CIM)425
尚未招募
2 期
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disordersCardiovascular, renal and respiratory disorders in convalescent patients from SARS-CoV-2 infectionCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirus/complicationsRespiratory Tract InfectionsCardiovascular InfectionsKidney DiseasesRPCEC00000376Center of Molecular Immunology (CIM)135
暂停
2 期
Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines.Patients with Non-Hodking LymphomaRPCEC00000096Center of Molecular Immunology88
已完成
3 期
Effectiveness and safety of ior EPOCIM in anemia in premature infant.Anemia of preterm newbornRPCEC00000088Center of Molecular Immunology(CIM)72
暂停
3 期
EPOCIM in benign prostatic hyperplasia.Benign prostatic hyperplasiaRPCEC00000092Center of Molecular Immunology(CIM)306